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Epithelial Naþ/Hþ exchange is a pleiotropic membrane
transport mechanism that participates in intestinal NaCl
transport, in the regulation of basic cellular functions and
the extracellular milieu to facilitate other nutrient absorp-
tion, and to regulate the gut microbial microenvironment. In
this review, we summarize the ﬁndings describing the basic
roles of Naþ/Hþ exchange and the consequences of its
dysregulation in the pathogenesis of gastrointestinal
disorders.
Severalmembers of the SLC9A family of NaD/HD exchangers
are expressed in the gut, with varying expression patterns
and cellular localization. Not only do they participate in the
regulation of basic epithelial cell functions, including con-
trol of transepithelial NaD absorption, intracellular pH
(pHi), cell volume, and nutrient absorption, but also in
cellular proliferation, migration, and apoptosis. In addition,
they modulate the extracellular milieu to facilitate other
nutrient absorption and to regulate the intestinal microbial
microenvironment. NaD/HD exchangers are frequent
targets of inhibition in gastrointestinal pathologies, either
by intrinsic factors (eg, bile acids, inﬂammatory mediators)
or infectious agents and associated microbial toxins. Based
on emerging evidence, disruption of NaD/HD exchange
activity via impaired expression or function of respective
isoforms may contribute not only to local and systemic
electrolyte imbalance, but also to the disease severity via
multiple mechanisms. Here, we review the current state of
knowledge about the roles NaD/HD exchangers play in the
pathogenesis of disorders of diverse origin and affecting
a range of gastrointestinal tissues. (Cell Mol Gastroenterol
Hepatol 2016;-:-–-; http://dx.doi.org/10.1016/
j.jcmgh.2016.09.010)
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uted to members of the cation/proton antiporters (CPA)
superfamily.1,2 Among the 4 inclusive families: CPA1, CPA2,
Pho1 phosphate permease, and Naþ-transporting carboxylic
acid decarboxylase, the CPA1 (SLC9A) family contains the
best-characterized plasmalemmal and intracellular isoformsREV 5.4.0 DTD  JCMGH171 proof  24(SLC9A1-9). In addition, the SLC9B subgroup consists of 2
Naþ/Hþ antiporter isoforms, Naþ/Hþ antiporter 1 and Naþ/
Hþ antiporter 2 (SLC9B1 and SLC9B2). In the gut, expression
of all NHE isoforms except NHE5 have been described.
NHE1 (SLC9A1), NHE2 (SLC9A2), NHE3 (SLC9A3), and NHE8
(SLC9A8) not only have been implicated in regulating the
basic functions of the epithelial cells, including control of the
intracellular pH (pHi), acidic mucosal microclimate, cell
volume, and nutrient absorption, but also in cell prolifera-
tion,3 cell migration,3,4 and apoptosis.5 Intestinal expression
of NHE4 (SLC9A4) in the small and large intestine remains
controversial. Although gastric expression and function have
been conﬁrmed,6,7 its presence in the intestine, at least in
rodents, was contested.7 In light of these observations, the
interpretation of the more recent studies on the functional
contribution of NHE4 to pH regulation in the human colonic
crypts8,9 has to be performed with care, although species
differences may account for the reported discrepancies.
As a principle, Naþ/Hþ exchangers use energy stored in
the form of the electrochemical Naþ concentration gradient
developed across the plasma membrane (secondary active
transport) by the basolateral Naþ/Kþ-adenosine triphos-
phatase. NHE is a critical mechanism for transepithelial
movement of Naþ and HCO3
- (and thus for luminal and sys-
temic salt, volume, and acid-base homeostasis) (Figure 1). It
also serves as a supporting role for other nutrient trans-
porters by providing the proton gradient for the proton-
coupled absorption of amino acids, peptides, organic
anions, short-chain fatty acids, folate, and iron.10,11 Only
mutations in the NHE6 or NHE9 genes have been linked to
human disease (X-linked mental retardation and familial










Figure 1. Simpliﬁed depiction of the apical Naþ/Hþ exchange
in transepithelial sodium, glucose, and water absorption. The
inward Naþ gradient (low intracellular [Naþ]) is maintained by
the basolateral Naþ/Kþ-adenosine triphosphatase (NKA),
which provides the driving force for several secondary active
transporters membrane transport proteins that import
glucose, amino acids (not shown), and other nutrients into the
cell by use of the sodium gradient. The intracellular concen-
tration of potassium is coordinated by basolateral efﬂux via
Kir7.1 (potassium inwardly rectifying channel, subfamily J,
member 13, KCNJ13). Electroneutral NaCl absorption is
driven by parallel Naþ/Hþ and Cl/HCO3
- exchange, the latter
mediated by down-regulated in adenoma (DRA; SLC26A3),
and putative anion transporter 1 (PAT1; SLC26A6). This
coupled activity is made possible by carbonic anhydrase,
which provides intracellular HCO3
-. NHEs are cross-regulated
with SLC26 family members and the Cl- and HCO3
- trans-
porting CFTR. In addition to Naþ/D-glucose apical transport,
SGLT1 activity stimulates NHE3 via an increased amount of
apical NHE3 (see section Contribution of Naþ/Hþ Exchange
to the Efﬁcacy of Oral Rehydration Therapy). GLUT2
(glucose transporter 2, SLC2A2) provides a basolateral exit
route for glucose. ClC-2 (chloride channel protein 2, CLCN2)
is capable of basolateral Cl- secretion, although its key role
appears to be the regulation of intestinal barrier function by
altering tight junction composition and recovery from injury.
An additional route of electrogenic Naþ transport is provided
by apical Naþ channels (not shown).
2 Gurney et al Cellular and Molecular Gastroenterology and Hepatology Vol. -, No. -recently has Janecke et al14 showed novel recessivemissense,
splicing, and truncation mutations in the NHE3-encoding
SLC9A3 gene as being linked to the pathogenesis of congen-
ital sodium diarrhea. Non–genetically based functional al-
terations of intestinal NHEs also have been linked withREV 5.4.0 DTD  JCMGH171 proof  24epithelial dysfunction. Details on the molecular mechanisms
of regulation of expression and function of NHEs are beyond
the scope and limit of this article, but have been covered
comprehensively in other reviews.15–18 In this review, we
summarize the current state of knowledge regarding the
physiological roles of NHE isoforms in the gut, and roles that
aberrant epithelial Naþ/Hþ exchange plays in the context of
gastrointestinal disorder pathogenesis.
NaD/HD Exchange in Esophageal and
Gastric Pathology
The Role of NHE1 in the Esophageal Epithelium
in Barrett’s Esophagus and in the Progression to
Esophageal Adenocarcinoma
Barrett’s esophagus is a precancerous condition charac-
terized by the metaplasia of columnar epithelium with goblet
cells that replace the normal squamous stratiﬁed epithelium
in response to chronic reﬂux of gastric acid and bile acids.
Although it is thought to represent a protective adaptive
response to noxious components of the gastric chyme,
metaplasia also is associated with an increased risk of
esophageal adenocarcinoma. When esophageal luminal
acidity reaches a pH of 2.0, the microenvironment adjacent to
the surface cells of the stratiﬁed squamous epithelium is
reduced to a pH of 2.0–3.0.19 On exposure to acid, esophageal
epithelial cells regulate their pH primarily via the combined
actions of Naþ/Hþ antiport and Naþ-dependent Cl-/HCO3
-
exchange.20 NHE1 is the sole plasmalemmal Naþ/Hþ
exchanger isoform expressed in the rabbit and rat
esophagus,21 and is regulated allosterically (activated) by
reduced pHi in a protein kinase C (PKC)-dependent
mechanism.22 In addition, epidermal growth factor (EGF),
abundant in the saliva, exerts a cytoprotective effect in acid-
exposed cells via Ca2þ/calmodulin- and PKC-dependent
activation of NHE1.23 Consistent with that, patients with
low salivary EGF levels were found to be susceptible to
severe esophageal damage as a potential consequence of
gastroesophageal reﬂux and to form a high-risk group for the
development of Barrett’s esophagus.24,25 NHE1 expression is
increased in patients with gastroesophageal reﬂux disease26
and in Barrett’s esophagus,27 where it likely represents a
cellular defensive mechanism to manage the acute and
chronic acid overload. Bile acids present in reﬂux chyme
reduce the ability of the cells to control their pHi by nitric
oxide–mediated NHE1 inhibition, thus leading to increased
DNA damage and potentially to mutations and cancer
progression.27
However, NHE1 has diverse physiological roles extend-
ing well beyond pHi and cell volume control, including cell
proliferation, growth, migration, and apoptosis, and
contributes to pathologic processes such as cancer cell
invasion and heart failure.28,29 In a Barrett’s adenocarci-
noma cell line, acid pulse-induced NHE1 activity correlated
with increased proliferation, which could be reduced by
inhibition of NHE1 or PKC.30 This ﬁnding led to a somewhat
paradoxic proposal that NHE1 inhibition may be of
therapeutic value in Barrett’s esophagus and prevention of
its progression to cancer.November 2016  7:48 pm  ce DVC
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The integrity of the gastric epithelium is essential for
protection from noxious luminal contents, which include
gastric acid, proteases, and food-borne pathogens. As a
consequence of damage to the surface epithelium, adjacent
healthy cells rapidly migrate into the injured area to restore
the mucosal barrier, and failure of this restitution process
may lead to ulceration. Expression and activity of NHE1, and
to a lesser extent NHE2 and NHE3, has been described in
gastric myoﬁbroblasts, cells that play a central role in
wound healing, deposition of the extracellular matrix, and
epithelial function.31 These functions are correlated tightly
with the myoﬁbroblasts’ ability to migrate and proliferate
within the subepithelial compartment. NHE1 and its
stimulation by insulin-like growth factor-II and carbachol
has been postulated to contribute to human gastric myoﬁ-
broblast migration and to be indispensable for insulin-like
growth factor-II–induced human gastric myoﬁbroblast
proliferation.31 Gastric epithelium expresses 5 NHE iso-
forms: apical NHE2 (in surface/neck mucous cells), apical
NHE3 (in rat but not rabbit parietal cells), apical NHE8
(mouse fundic and pyloric glands), basolateral NHE1 (all
cells), and basolateral NHE4 (in parietal and chief
cells).32–34 Initially, NHE1 was implicated in gastric repair in
guinea pig mucosa in vitro.35,36 Later studies with more
deﬁnitive mouse knockout models, and the use of intravital
2-photon laser microscopy after injury, showed that it is
NHE2 and not NHE1 that is required for the cytoprotective
effects of trefoil factor 3 in the gastric epithelium.37 These
ﬁndings were also in agreement with the in vitro studies by
Furukawa et al,38 and in the description of progressive
gastritis and gastric atrophy with loss of parietal cells in
NHE2-/- mice.39,40 Consistent with its expression pattern,
loss of NHE4 in knockout mice resulted in reduced numbers
of parietal cells, a loss of mature chief cells, increased
numbers of mucous and undifferentiated cells, and an
increase in the number of necrotic and apoptotic cells.6
More recent studies from our laboratory also showed that
gastric expression of NHE8 was critical for the maintenance
of bicarbonate secretion by the Cl-/HCO3
- exchanger down-
regulated-in-adenoma (DRA; SLC26A3) and the associated
mucosal protection. Compared with their wild-type litter-
mates, mice lacking NHE8 had a higher incidence of gastric
ulcer formation.32 Although the mechanism responsible for
DRA down-regulation is not yet clear, it appears to be a
phenomenon consistent across organs because it was
described also in the colon,41 conjunctiva, the cornea, and
the lacrimal glands.42
Intestinal NaD/HD Exchange in
Diarrheal Diseases
Congenital Sodium Diarrhea
Congenital sodium diarrhea (CSD) is a rare autosomal-
recessive diarrheal disorder originally described in 2
patients in 1984 and 1985.43,44 To date, there have been
fewer than 50 CSD cases reported in the literature.45 Before
birth, polyhydroamnios (an excess of amniotic ﬂuid in the
amniotic sac) is observed, which is suggestive of an increaseREV 5.4.0 DTD  JCMGH171 proof  24in colonic output by the fetus. After birth the disease is
characterized by the secretion of a large volume of
persistent high Naþ diarrhea, often mistaken for urine,
which leads to irritability, dehydration, and metabolic
acidosis.45 Although profuse diarrhea continues, electrolyte
replacement therapy promotes normal growth and
development.46
Two of the early reports of CSD linked diarrhea to defec-
tive NHE in the jejunum,44,46 although the identity of the
transporter remained unknown. In an attempt to identify the
speciﬁc isoform, Muller et al47 studied a small CSD cohort of 5
infants from 2 inbred Austrian families and found no contri-
bution from any of the 6 then known NHEs. Subsequent
analyses showed additional intestinal and corneal patho-
physiology (intestinal epithelia dysplasia and corneal
epithelial erosions) among other symptoms accompanying
high Naþ diarrhea. These affect approximately a third of CSD
patients, are referred to as the syndromic CSD form, and have
been linked to a mutation in SPINT2.48 The classic or non-
syndromic form of CSD is linked strongly to defective NHE
activity, and, recently, using a cohort of 18 patients from 16
families, Janecke et al45 determined that a variety of muta-
tions (point, missense, and truncation) in the NHE3-encoding
SLC9A3 gene occurred in a subset (9 of 18) of the studied CSD
cases. The identiﬁed SLC9A3 mutations included 1 whole-
gene deletion, 1 splicing, and 2 frame-shift mutations, all of
which were expected to abolish protein production. Four
missense mutations/variants, p.Arg382Gln, p.Ala311Val,
p.Ala269Thr, and p.Ala127Thr, were tested in vitro, and all
but p.Ala127Thr (benign variant) conferred decreased basal
Naþ/Hþ exchange activity.45
In addition, an activating mutation in the catalytic
domain of the gene GUCY2C also was identiﬁed and may
account for 20% of sporadic CSD cases.49,50 This mutation
likely is linked mechanistically to hyperactivation of the
cystic ﬁbrosis transmembrane conductance regulator
(CFTR)49 and reduced NHE3 function via increased intra-
cellular cyclic guanosine monophosphate (cGMP) and NHE3
inhibition via a cGKII kinase-dependent mechanism.51,52
Consequently, NHE3 inhibition may contribute to at least
70% of CSD cases. Additional research is required to iden-
tify the remaining contributing factors, especially in the fetal
and neonatal period when the contribution of NHE3 to total
epithelial NHE is thought to be minimal. Although NHE8 has
a reciprocal ontogenic pattern of expression, with higher
levels in young than in older animals,53,54 no mutations
were found in the exonic regions of the SLC9A8 gene in a
small cohort of 5 CSD patients.54Inhibition of Naþ/Hþ Exchange During
Infectious Diarrhea
Diarrhea caused by enteric infections is a major factor in
morbidity and mortality worldwide. The mechanisms are
multifactorial and include alterations in motility, changes in
paracellular permeability, loss of absorptive surface, and
changes in electrolyte ﬂuxes. A signiﬁcant component of
altered electrolyte ﬂux in infectious diarrhea is increased
chloride secretion via activation of apical chloride channels,November 2016  7:48 pm  ce DVC
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ever, there is a signiﬁcant component or subset of infectious
diarrheal cases related to inhibition of Naþ and ﬂuid
absorption. The underlying mechanism for the latter is a
reduction in Naþ absorption via impaired NHE activity, with
the affected NHE isoforms and the mechanisms involved
varying among pathogens. During infection with Vibrio chol-
erae, a prime example of secretory diarrhea, cholera toxin is
capable of reducing epithelial Naþ absorption via cyclic
adenosine monophosphate (cAMP)-dependent inhibition of
NHE2 and NHE3.56 Extrapolating from the known mecha-
nisms governing NHE regulation,57,58 one could generalize
that bacterial pathogens that increase intracellular Ca2þ,
cAMP, and/or cGMPconcentration inhibit electroneutralNaCl
absorption. Indeed, this was shown in mouse models of
infection with Salmonella typhimurium, Shigella dysenteriae
type 1 toxin, and Campylobacter jejuni.59–61
However, other mechanisms leading to NHE inhibition
also have been described.
Clostridium difﬁcile, the leading cause of nosocomial
diarrhea and pseudomembranous colitis, also exerts
inhibitory effects on epithelial NHE. C difﬁcile toxin B inhibits
Rho-family guanosine triphosphatases and alters the inter-
action between NHE3 and the microvillar actin cytoskeleton
to facilitate its internalization and loss of function.62 C difﬁcile
toxin B also was shown to disrupt the stimulating effects of
rho guanine nucleotide exchange factor 7, which, along with
SH3 and multiple ankyrin repeat domains 2, maintains apical
membrane NHE3 expression.63More recently, Engevik et al64
postulated that NHE3 inhibition by C difﬁcile toxin resulted in
alteration of the intestinal environment and gut microbiota,
which could facilitate colonization and expansion of the
pathogen. They showed that when compared with healthy
controls, decreased expression of NHE3 in infected patients
correlated with increased Naþ and pH of the stools, increased
Bacteroidetes and Proteobacteria, and decreased Firmicutes
phyla. Interestingly, in vitro growth of C difﬁcile was
promoted by increased Naþ and an alkaline media pH;
consequently, the investigators concluded that inhibition of
NHE3 creates an altered environment favored by C difﬁcile.64
Several classes of pathogenic E coli strains are responsible
for diarrheal outbreaks. These include enteropathogenic E
coli (EPEC), enterohemorrhagic E coli, enterotoxigenic E coli,
enteroaggregative E coli, enteroinvasive E coli, and diffusely
adherent E coli. A variety of NHE-independent mechanisms
that contribute to diarrheagenic effects of EPEC are known
(outside the scope of this review).65 Surprisingly, the effects
of EPEC in vitro (Caco-2 BBE, HT-29 cells, and T84 cells) were
isoform-speciﬁc, with signiﬁcant increases in NHE1
(basolateral) and NHE2 (apical) activity and a concurrent
50% inhibition ofNHE3.66 In a follow-up study, Hodges et al67
showed that the inhibitory effects of EPEC on NHE3 were
dependent on E. coli secreted protein F-like protein from
prophage U (EspF), a component of the EPEC type III secre-
tion system. On the host side, Chen et al68 showed that E coli
heat-stable enterotoxin, which binds to guanylate cyclase-C in
the luminal enterocyte membrane and increases intracellular
cGMP levels,69 requires the presence of the regulatory
structural domain (post synaptic density protein, DrosophilaREV 5.4.0 DTD  JCMGH171 proof  24disc large tumor suppressor, and zona occludens-1 protein)
(PDZ) adaptor protein sodium hydrogen exchange regulatory
factor (NHERF)2.68 The downstream effector of increased
cGMP, cGKII, is a part of a NHE3 signaling complex,70 and
inhibition of NHE3 activity by cGMP/cGKII requires NHE3
protein phosphorylation at Ser554 and Ser607,52 although the
relationship of NHERF2/cGMP/cGKII in the context of expo-
sure to E coli enterotoxin is not yet clear. Increased apical
NHE2 activity may be compensatory to the loss of NHE3,
although it remains unknown whether it outweighs NHE3
inhibition in vivo. Contrary to NHE3-/- mice,71 targeting of the
SLC9A2 gene did not result in diarrhea,39,72 suggesting that
NHE2 is not amajor absorptive Naþ/Hþ exchanger. Inhibition
of NHE4 in T-84 cells by the heat-stable enterotoxin of
enterotoxigenic E coli also has been reported, although
the relevance of this ﬁnding is unclear considering the
inconsistent data on intestinal expression of this isoform.7,9
Less is known about the role of NHE in diarrhea during
viral gastroenteritis. Astroviral infections have been
associated with Naþ malabsorption, and 1 study suggested
that infection leads to decreased levels of NHE3 in the
insoluble protein fraction in the enterocytes, presumed to
represent the apical membrane.73 Recently communicated
data from rotavirus-infected patients showed that both
NHE2 and NHE3 proteins are down-regulated, and the
remaining NHE3 is mislocalized.74Contribution of Naþ/Hþ Exchange to the Efﬁcacy
of Oral Rehydration Therapy
The glucose transporter SGLT1 uses a Naþ gradient to
transport Naþ and glucose at a 2:1 stoichiometric ratio
against a glucose gradient.75 In each cycle, a sugar
molecule is co-transported with Naþ across the cell, which
is accompanied by 260 water molecules.76 This mecha-
nism was calculated to account for 5 L of water absorbed
per day in the human intestine and formed the molecular
basis of oral rehydration therapy aimed to control mor-
tality associated with cholera and other infectious diar-
rheal diseases.77 Lin et al78 showed a key NHE3
contribution to the efﬁcacy of oral rehydration solution.
They showed that SGLT1-mediated Na-glucose co-trans-
port stimulates NHE3 activity in vivo by a protein kinase
B (Akt/PKB)- and NHERF2-dependent pathway. This in-
crease was associated with increased brush-border NHE3
recruitment through its release from the endosomal
storage pool. Activation of NHE3 by glucose reversed
cholera toxin–induced NHE3 inhibition, a phenomenon
that at least partially may explain the efﬁcacy of oral
rehydration solution (ORS).78 In 2004, both the World
Health Organization and the United Nations Children’s
Fund suggested the supplementation of ORS with zinc.
This recommendation was based on observations linking
a reduction in tissue and an increase in fecal zinc levels in
infants and children with diarrhea,79 and that zinc deﬁ-
ciency is responsible for decreased net water and sodium
transport from the small and large intestine.80 Clinical
studies showed a decrease in diarrheic stool volume and
episode duration when zinc was administered inNovember 2016  7:48 pm  ce DVC
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effects of zinc,82 Hoque et al83 showed that zinc not only
stimulated basal NHE3 activity by 50%, but it also
counteracted forskolin-induced cAMP-mediated NHE3
inhibition. Although conventional ORS targets primarily
small intestinal Naþ and water absorption, an improved
formulation has been proposed to target the colon as
well.84 In this approach, D-glucose is replaced with a
relatively amylase-resistant cornstarch. Although some of
the starch is broken down enzymatically in the jejunum to
stimulate Naþ absorption, most of it would enter the co-
lon where it could be fermented to short-chain fatty acids
such as propionate, butyrate, and acetate by the resident
bacteria. Butyrate increases the expression and/or activ-
ity of apical NHEs85–88 and aids in transepithelial Naþ
absorption via a neutral linked Naþ absorptive process
that exchanges short-chain fatty acids for OH- ions along
with the apical Naþ/Hþ exchange. In a small randomized
clinical trial, this ORS formulation performed better than
standard ORS by reducing both the duration and volume
loss of severe acute diarrhea.84 Two other randomized
controlled trials with the addition of high-amylose maize
starch to ORS performed in South India have shown a
substantial decrease in diarrhea duration in both adults
and children hospitalized for acute diarrhea.89,90 One
drawback of such modiﬁed ORS is the precipitation of the
starch in the ORS formulation. New formulations con-
taining an antisettling agent have been proposed and
clinical trials were reported in 2014 by Binder et al91 as
underway.Modulation of Intestinal Naþ/Hþ Exchange in
Noninfectious Diarrhea Associated With
Immunosuppression (Rapamycin)
Rapamycin or sirolimus is a drug isolated from the
actinomycete Streptomyces hygroscopius that shows immu-
nosuppressive, antiproliferative, and antifungal properties.
Rapamycin and its analogs (Rapalogs) have been shown to
inhibit the activity of mammalian or mechanistic target of
rapamycin (mTOR).92 mTOR is a serine-threonine kinase
that is known to form 2 different catalytic complexes, the
mTOR complex 1 or 2 (mTORC1 or mTORC2), and to induce
autophagy.92 Rapamycin administration inhibits mTORC1,
while long-term use partially inhibits mTORC2. Its use to
prevent organ transplant rejection and to treat lym-
phangioleiomyomatosis is associated with several side ef-
fects, which include diarrhea. Among patients receiving
postrenal transplant rapamycin treatment and in those
hospitalized for noninfectious diarrhea, ileal NHE3 expres-
sion was reduced at the apical membrane.93 Of 367 records
of renal transplant cases at the Albany Medical College, 20
patients had 39 events of acute, severe diarrhea requiring
hospitalization. In all events, rapamycin levels at the time of
diarrhea were increased signiﬁcantly (2–7 times higher than
the baseline levels), and in all cases diarrhea resolved within
3–5 days after the serum rapamycin levels returned to
baseline.93 This ﬁnding was reproduced in rapamycin-
treated wild-type, but not in autophagy-resistant, Atg7-/-REV 5.4.0 DTD  JCMGH171 proof  24mice. Deletion of mTOR in mice also led to reduced NHE
activity, luminal accumulation of ﬂuid, and reduced levels of
NHE3 and NHERF1.93
Intestinal NaD/HD Exchange in Clinical
and Experimental Inﬂammatory
Bowel Diseases
Inﬂammatory bowel disease (IBD) is a group of chronic
inﬂammatory diseases that includes Crohn’s disease (CD)
and ulcerative colitis (UC). Both conditions are character-
ized by immune system activation, microbial dysbiosis, and
disruption of the epithelial barrier, which may lead to
bacterial translocation, the latter being a more prominent
feature of CD.94 Alterations in the function of epithelial cells
in IBD extend into transcellular nutrient transport.95 In
some instances, those alterations of transport protein
complexes at the apical or basolateral membranes have
consequences transcending their basal functions as nutrient
or electrolyte transporters to modulate epithelial barrier
function and gut microbiota, potentially shaping the
immune response in the course of IBD.Inhibition of Intestinal Naþ/Hþ Exchange as a
Contributor to Inﬂammation-Associated Diarrhea
Diarrhea is one of the common symptoms in patients
with IBD, occurring in approximately 50% of acute ﬂare-ups
in CD and in nearly all UC patients.96 The pathophysiology of
diarrhea in IBD is complex and multifactorial. It involves
altered intestinal motility as well as abnormal epithelial ion
transport and defective Naþ absorption in the colonic
mucosa in particular.97,98 Contrary to infectious diarrhea in
which active and excessive Cl- secretion is predominant, in
IBD, both electrogenic Naþ transport mediated by sodium
channels99–101 as well as electroneutral NHE and coupled
Na-Cl absorption are reduced.102 At least for UC, a model
was proposed whereby the associated diarrhea is the result
of a combination of factors: increased paracellular perme-
ability to monovalent ions, reduction of electrogenic Naþ
absorption (secondary to decreased apical Naþ channel and
basolateral Naþ/Kþ-adenosine triphosphatase expression),
electroneutral Naþ absorption and coupled Naþ-Hþ/
Cl--HCO3
- exchange, and as a result compromised active Cl-
absorption.102
The mechanisms involved in the inhibition of epithelial
NHEs in IBD are not well deﬁned and conﬂicting results have
been published. Interferon g inhibits the expression and
function of NHE3 and NHE2 both in vitro and in vivo.103
Inhibition of NHE3 expression and activity also has been
described in several experimental models of colitis, including
interleukin (IL)2-/- mice,104 and in dextran sulfate sodium–
and trinitrobenzene sulfonic acid–induced colitis.105 The
latter study described decreased NHE3 protein expression in
sigmoid mucosal biopsy specimens from most of the cases of
active UC and/or CD, in ileal mucosal biopsy specimens of
active CD, as well as in approximately 50% of sigmoid biopsy
specimens from inactive UC or CD. Siddique et al106 showed
that in both the untreated and treated patients with CD andNovember 2016  7:48 pm  ce DVC
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more, NHE3 messenger RNA (mRNA) was reduced only in
CD, but not in patients with UC. However, in IL10-/- mice,
NHE3 activity, measured in the apical enterocytes within
isolated colonic crypts, was decreased signiﬁcantly without
altered NHE3 expression and localization.107 The in-
vestigators speculated that decreased expression of 2 key
NHE3-regulatory proteins, SLC9A3 regulator 2 (SLC9A3R2/
NHERF-2) and PDZ domain containing 1 (PDZK1), may be
responsible for decreased NHE3 activity.107 Additional
studies with UC patients by Yeruva et al108 and Farkas
et al109 showed a signiﬁcant reduction of NHE3 activity
despite the preserved protein and mRNA expression, thus
arguing for post-translational regulation of the antiporter
activity. In an in vivomodel of diarrhea mediated by anti-CD3
monoclonal antibody–induced T-cell activation, Clayburgh
et al110 showed that in the jejunum, tumor necrosis factor
induces NHE3 internalization. PKCa activation triggered by
tumor necrosis factor was responsible for NHE3 internali-
zation and the resulting Naþmalabsorption.110 Although it is
clear that the NHE3-mediated apical Naþ/Hþ exchange and
epithelial Naþ absorption are inhibited in IBD, the exact
mechanism remains unclear and may depend on the speciﬁc
disease, segment involved, and/or the severity of
inﬂammation.
NHE8 has a broader expression pattern than other apical
NHEs.53,111,112 Moreover, its expression is not limited to the
apical membrane; in vitro studies with ectopically expressed
NHE8 have shown that it is both present and functional in
the trans-Golgi network and multivesicular bodies.113 It is
broadly expressed in the colon, including the goblet cells,
where it participates in the regulation of mucin 2 (Muc2)
expression and mucous secretion.41,114,115 Although we
observed a dramatic decrease in the expression of NHE8 in
UC patients (Li et al, unpublished data), loss of NHE8
expression and activity may not contribute to inﬂammation-
associated diarrhea directly because NHE8-/- mice do not
show symptoms of impaired Naþ absorption or diarrhea.41
The consequences of NHE8 deﬁciency in IBD may be more
related to microbial–host interactions, as discussed in the
next section.
Both the role of the basolateral NHE1 and the potential
changes in its expression and/or activity in the colonic
epithelial cells in clinical and experimental IBD remain
unclear, and the available data are inconsistent. Expression
of NHE1 mRNA and protein was increased in both acetic
acid and trinitrobenzene sulfonic acid–induced colitis in
rats,116 and nonspeciﬁc pharmacologic NHE inhibition with
amiloride was deemed beneﬁcial in rodent models of
IBD.117,118 However, in human patients, opposing data have
been published. Contrary to the same group’s earlier rat
data, Khan et al119 and Siddique and Khan120 showed
decreased NHE1 mRNA in the biopsy specimens of UC and
CD patients, whereas Farkas et al109 showed consistently
increased NHE1 activity and expression in the inﬂamed
mucosa of UC patients. The importance of these controver-
sial ﬁndings remains unclear. Although it may be
consequential to some aspects of epithelial cell function, the
notion that “NHE1 suppression may reduce an uptake ofREV 5.4.0 DTD  JCMGH171 proof  24sodium chloride and water from the inﬂamed colonic lumen
and thus contribute to diarrhea”119 currently lacks
experimental support.Apical Naþ/Hþ Exchange as a Modulator of the
Gut Microbiome and Inﬂammatory Response
During Colitis
The lumen of the gastrointestinal tract is a habitat for 100
trillion bacterial cells, which form a virtual organ.121 This
gastrointestinal bacterial consortium, collectively referred to
as the gut microbiome, is a highly functional, complex, and
dynamic entity. The composition of this virtual organ, known
as the gutmicrobiota ormicrobiome, generally is conserved at
the phylum level and is unique for each individual at lower
taxonomic (genus and species) levels. The adult colon is
colonized predominantly by 2 phyla, Bacteroidetes and
Firmicutes, followed by Proteobacteria and Actinobacteria.122
Cells of both the innate immune system (including epithelial
cells) as well as of the adaptive immune system can sense
microorganisms or theirmetabolic products and translate the
signals into host physiological responses, which in turn can
regulate the gut microbial ecology.123,124 This cross-talk is
essential for normal gut development, maturation of the
immune system, optimal nutrient bioavailability, participa-
tion in xenobiotic and hormone metabolism, and the main-
tenance of the epithelial and immune cell microenvironment.
Any perturbations in microbial–host homeostasis results in
dysbiosis, a detrimental shift in the composition or microbial
abundance, with consequences ranging from enteric
infections,125,126 colorectal cancer,127 and autoimmune
diseases,128 through metabolic syndrome (type 2 diabetes
and obesity),129 to neuropsychiatric diseases and autism
spectrum disorders.130–133
Dysbiosis in both IBD patients and animal models is
characterized by reduced general biodiversity,134 expanded
relative abundance of the Bacteroidetes, Proteobacteria, and
Actinobacteria phyla, decreased abundance of Firmicutes,135
and, importantly, the presence of Clostridia species
belonging to the clostridia IV and XIVa clusters, the major
butyrate-producing bacteria and inducers of colonic
CD4þFoxP3þ T-regulatory cells.136 Similar changes have
been observed in mouse models of IBD.137–139 The mecha-
nisms by which the gut microbial community is affected by
the inﬂammatory process, or whether dysbiosis is sufﬁcient
to induce and/or modulate mucosal immune responses,
remain a subject of debate. Although some studies have
indicated that dysbiotic communities can be colitogenic upon
transmission to wild-type mice,140 others have shown that
mucosal bacteria from UC patients only confer susceptibility
and are not sufﬁcient to induce disease in untreated or
otherwise nongenetically manipulated hosts.141
Wehypothesized that inhibition of epithelial NHE, common
in IBD patients, may lead to altered epithelial cell function and
mucosal milieu that could lead or contribute to the observed
shifts inmicrobial gut ecology and, as a consequence, inﬂuence
mucosal inﬂammation (Figure 2). Indeed, mice lacking the
dominant epithelial apical NHE isoform NHE3, when raised in










Figure 2. Summary graph illustrating the roles of NHE3 and NHE8 and the consequences of their inhibition during mucosal
inﬂammation. IEC, intestinal epithelial cell; Th, T-helper.
- 2016 Pathophysiology of Intestinal NHE 7with mild diarrhea.142 Colitis symptoms were alleviated by
broad-spectrum antibiotics and reduced by rederivation into a
barrier facility.142,143 NHE3-/- mice develop microbial dysbio-
sis similar to IBD patients.143 Although they appear to have
normal mucous thickness, structure, and Muc2 mRNA
expression, higher bacterial penetrance with increased bac-
terial adhesion to the mucosa and bacterial translocation was
described, similar to IL10-/- mice.142,144 These ﬁndings sug-
gested that mucus thickness alone is not a major determinant
of bacterial penetration, and that other factors may contribute
to mucosal bacterial penetration in IBD.144 It is plausible,
however, that the molecular structure of mucin 2 (MUC2)
polymers within the inner layer may change with impaired
apical Naþ/Hþ exchange. Because MUC2 is packed into
secretory granules in the goblet cells, the organellar pH
changes from 7.2 in the endoplasmic reticulum to 6.0 in the
trans-Golgi network, and to5.2 in the secretory granulae, along
with increasing Ca2þ concentration.145 Upon secretion, and
before the 1000-fold expansion, it remains densely packed to
form the impenetrable for bacteria inner stratiﬁed layer,which
is best preserved at a pH of 6.2 in the form of sheets of
N-terminal trimers.145 Disruption of the regulatory mecha-
nisms responsible for maintenance of the acidic microclimate
could make the MUC2 network structure more penetrable
for bacteria. However, this would require experimental
conﬁrmation.
Importantly, NHE3-/- mice are highly susceptible to
experimental colitis,146,147 although the relative contribu-
tions of epithelial dysfunction and microbial dysbiosis still
are unclear. Most recently, our group showed that in adoptive
T-cell transfer colitis, NHE3 deﬁciency and the associated
dysbiosis dramatically accelerated and exacerbated the
disease, increased mucosal CD4þ T-cell and neutrophil
homing, and increased intestinal permeability, all of whichREV 5.4.0 DTD  JCMGH171 proof  24was attenuated with broad-spectrum antibiotics.148
Strikingly, a dysbiotic microbiome was associated more
strongly with NHE3 deﬁciency than with T-cell–mediated
colitis per se.148 We concluded that Naþ/Hþ exchange is,
therefore, a crucial process for maintaining microbial
homeostasis within the gut and that its disruption in IBD is
likely a strong contributor to dysbiosis, which in turn affects
the progression and severity of disease. Another group also
showed that higher ileal luminal Naþ concentration, and not
changes in pH, is responsible for the relative expansion of
Bacteroides thetaiotaomicron and expression and activity of
fucosylase FUT2.149B thetaiotaomicron has been shown to be
colitigenic,150 and an aberrantly high IL8 response to B
thetaiotaomicron has been shown in CD patients,149 ﬁndings
that may provide a link between inhibition of NHE3 and
mucosal neutrophil inﬂux in IBD.
As suggested earlier in this review, NHE8 also may
contribute to mucosal homeostasis through mechanisms
distinct from that of NHE3, possibly through its
as-yet-undeﬁned roles in the goblet cell function. Indeed, it is
down-regulated and confers higher susceptibility during
experimental colitis with a T-helper 2–like response.151,152
Reduced expression or absence of NHE8 also is related to
decreased Muc2 mRNA expression in goblets cells, and
decreased mucosal expression of antimicrobial peptides.114
NHE8-/- mice have reduced Muc2 expression, which also
could be reproduced in colonic organoids from this strain (Xu
et al, unpublished data), and show a reduced inner mucous
layer and closer proximity of luminal bacteria to the brush-
border membrane.152 Consequently, loss of NHE8 in vivo
led to higher adhesion of S typhimurium.152 In vitro, NHE8
small interfering RNA knockdown showed a similar increase
in S typhimurium adhesion, which appeared to be selective
and did not affect adhesion of a probiotic strain ofNovember 2016  7:48 pm  ce DVC
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NHE3 and NHE8 knockout mice suggest that their inhibition
during inﬂammation or infection, albeit acting via different
mechanisms, may be critical in shaping the host-microbial
homeostasis in the gut and affect mucosal immune
responses during IBD. The development of new pharmaco-
logic approaches to either prevention of inhibition of the 2
apical NHEs, or restoration of their activity, may be of sig-
niﬁcant beneﬁt to IBD patients not only as means of reducing
episodes of diarrhea, but possibly as means of modulating the
gut microbiome and host’s inﬂammatory response.
Therapeutic Targeting of Intestinal
NaD/HD Exchange
Potential for Modulation of Intestinal Fluid and
Naþ Absorption in Diarrheal and Inﬂammatory
Conditions by Targeting NHE3 Activity
As described earlier in this review, part of the success of
oral rehydration therapy and its modiﬁcations relies on the
modulation of electroneutral epithelial Naþ/Hþ exchange.
Considering the role of the C-terminus of the NHE3 protein in
forming regulatory complexes responsible for NHE3 endo-
cytic retrieval,18 Zachos et al153 postulated that a peptide
designed to mimic the region of the NHE3 protein involved in
the formation of the inhibitor regulatory complex (IRCX;
NHERFs 1–4, phospholipase C-g, casein kinase 2, and Ca2þ/
calmodulin-dependent protein kinase II) may increase the
apical pool of NHE3 and improve its activity. This 38–amino
acid decoy peptide dubbed IRCX complex formation stimu-
lated basal NHE3 activity by 40% and prevented inhibition of
NHE3 activity by both forskolin and carbachol, without
altering the stimulatory effect of EGF on NHE3 activity.153 In
addition, in vivo, IRCX complex formation prevented the
cholera toxin–induced increase in luminal ﬂuid accumula-
tion. It remains to be seen whether these promising data
translate into a viable treatment. However, it clearly shows
that the formation of the regulatory complexes at the C-ter-
minus of NHE3 represents an attractive target for compound
screening and development of drugs to stimulate NHE3 as
potentially useful in the treatment of infectious and nonin-
fectious diarrhea, and perhaps in modulating microbial and
inﬂammatory responses in IBD.
Inhibition of Intestinal NHE3 Activity as
a Treatment Modality for Hypertension,
Constipation-Predominant Irritable
Bowel Syndrome, and Hyperphosphatemia for
End-Stage Renal Disease Patients on Dialysis
On the opposite spectrum, excessive sodium intake and/
or reduced excretion in the intestine leads to sodium–ﬂuid
imbalances that result in hypertension, which then can lead
to vision impairment in addition to a variety of cardiovas-
cular and renal diseases such as heart failure, chronic
kidney disease, stroke, and coronary heart disease. Typi-
cally, hypertension is considered to be one of the most
common modiﬁable risk factors for cardiovascular disease
and death154 because it can be controlled by reducingREV 5.4.0 DTD  JCMGH171 proof  24dietary sodium intake.155 Unfortunately, compliance with a
low-salt diet is low.156 Drugs that limit intestinal sodium
absorption, given alone or in conjunction with other
antihypertensive medications, have been considered. To this
end, 2 oral nonabsorbable NHE3 inhibitors have been
developed, SAR218034 (SAR) and tenapanor. Pharmacoki-
netic analyses in rats, dogs, and human beings have shown
that neither of these compounds crossed the intestinal
barrier in biologically active doses,157,158 and tenapanor
was well tolerated in phase I clinical study.159 Both drugs
were found to increase fecal and reduce urinary Naþ
concentrations in rats (SAR and tenapanor) and human
beings (tenapanor). Not surprisingly, both drugs caused an
increase in luminal ﬂuid resulting from increased Naþ,
leading to loose stools (a laxative effect).157,158 In a spon-
taneously hypertensive rat model, SAR administration in
conjunction with sodium chloride–laden drinking water
markedly reduced systolic blood pressure.158 Furthermore,
in a salt-fed 5/6 nephrectomized rat model (a chronic
kidney disease model associated with hypertension, hyper-
volemia, cardiac hypertrophy, and arterial stiffening),
tenapanor reduced extracellular volume expansion, albu-
minuria, and blood pressure, in addition to promoting
protective cardiorenal effects such as reducing left ventric-
ular hypertrophy.157 Both drugs show enhanced effects if
administered in conjunction with an angiotensin-converting
enzyme inhibitor, which was deemed important in cases in
which hypertension could not be controlled by the admin-
istration of a single medication.157,158 However, more
recently, the development of tenapanor and SAR, and the
general concept of inhibition of intestinal Naþ/Hþ exchange
as an antihypertensive strategy, appears to have been
abandoned by Ardelyx (Fremont, CA) and Sanoﬁ (Paris,
France), respectively. Ardelyx continues the investigation
into the use of tenapanor and its close analogs in patients
with constipation-predominant irritable bowel syndrome
and for the treatment of hyperphosphatemia in end-stage
renal disease patients on dialysis.160,161 The potential of
NHE3 inhibitors as stool softeners in constipation-
predominant irritable bowel syndrome is obvious,
although it remains to be seen if they can be applied without
signiﬁcant adverse effects. A somewhat similar strategy to
modulate ion transport in constipation has been applied
recently to develop CFTR activator to increase the net
chloride output in the gut.162 The concept behind the use of
NHE3 inhibition in hyperphosphatemia is based on the
described increased fecal Pi excretion and reduced urinary
Pi excretion in NHE3 inhibitor-treated rats with chronic
kidney disease with vascular calciﬁcation, in which tena-
panor markedly reduced ectopic calciﬁcation and protected
renal function.161 The mechanism of this phenomenon re-
mains unclear. It also is not yet evident whether targeting
NHE3 would be more efﬁcacious and have less adverse ef-
fects that the Pi binders currently used clinically.Conclusions
NHEs are important regulators of a wide array of
processes on a cellular, tissue, and systemic level. TheNovember 2016  7:48 pm  ce DVC
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plasmalemmal isoforms, which play protective roles during
disease pathogenesis in a segment- and isoform-speciﬁc
fashion and are frequent targets of inhibition by microbial
or inﬂammatory stimuli. As such, future studies may bring
new approaches that selectively target NHEs in the gut to
enhance or inhibit their function for the beneﬁt of the
patients. Importantly, a large body of knowledge relies on
studies focused on individual isoforms, frequently with
knockout mice, while their true function always occurs in
the larger context of frequently interdependent trans-
porters, also subject to regulation during physiological and
pathophysiological conditions. Thus, more integrative
approaches to function, regulation, and targeting of NHEs in
gut-associated pathologies may be needed. Although the
usefulness of orally available inhibitors remains to be
established, the emerging focus on the development of
agonists of intestinal apical Naþ/Hþ exchange may provide
signiﬁcant beneﬁts to the future treatment of infectious and
inﬂammatory disorders of the gut.References
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